Precision CNS-specific biomarker measurement for Alzheimer’s disease
12 Feb 2026Plasma phosphorylated tau at threonine 217 (pTau 217) is currently the most effective blood biomarker for Alzheimer’s disease, demonstrating strong concordance with amyloid-β (Aβ) and tau PET imaging and the largest fold difference between amyloidnegative and amyloid-positive individuals.
This application note evaluates the performance of the SPEAR UltraDetect™ BD-pTau 217 Assay, designed to target CNS-specific pTau 217 species, in a memory clinic cohort and in a cohort of young healthy individuals.
Related Products
Request Quote for All Products
SPEAR UltraDetect™ BD-pTau 217 Assay Kit
Spear BioThe SPEAR UltraDetect™ BD-pTau 217 Assay enables highly sensitive and precise quantification of brain-derived pTau 217 in plasma. The only BD-pTau 217 assay delivering 100% quantifiability across healthy and diseased samples using just 1 µL of diluted plasma in a homogenous, wash-free format — enabling robust early detection, stratification, and longitudinal analysis of this ultra-low abundance biomarker. Verified for plasma samples. For research use only.